Literature DB >> 12219672

[Perioperative mortality in otorhinolaryngology tumor surgery].

H E Eckel1, O Goldschmidt, M Schauermann, H Knopf, M Streppel.   

Abstract

BACKGROUND: Perioperative mortality is an important factor for quality assurance in surgery. For ENT-surgery only sparse data has been published. PATIENTS AND METHODS: A retrospective analysis of 1054 interventions performed on 775 consecutive patients treated surgically for benign and malignant tumors of the head and neck was conducted during a 3-year period in 1995-1998.
RESULTS: Of these patients, 34.1% were female and 65.9% male. Age ranged from 4-88 years with a mean age of 54.8 years. 489 patients (63.1%) were treated for malignoma and 286 for benign tumors (36.9%). 0.9% (n = 7) of our patients (n = 775) died during the first 30 days after surgery. That means 0.66% of all surgical interventions (n = 1054) were followed by post-operative mortality. DISCUSSION: In otorhinolaryngological surgery, post-operative mortality seems to be acceptable and low compared to other medical disciplines. The challenge for surgery must be to reach and preserve low perioperative mortality rates in the future. Finding the individually correct indication for surgical treatment must be guaranteed in order to reach this aim.

Entities:  

Mesh:

Year:  2002        PMID: 12219672     DOI: 10.1007/s00106-001-0592-6

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  3 in total

1.  [Process optimization in ENT: clinical pathways and central induction area].

Authors:  O Göktas; F Fleiner; C Spies; H Krieg; K Bauer; B Sedlmaier
Journal:  HNO       Date:  2010-02       Impact factor: 1.284

2.  [Squamous cell carcinoma of the external ear. A carcinoma of old age which requires individualized therapy planning].

Authors:  G Lehnerdt; K A Metz; L Peine; K Jahnke; P Dost
Journal:  HNO       Date:  2004-06       Impact factor: 1.284

3.  [Surgical therapy of malignant melanoma of the external ear].

Authors:  P Dost; G Lehnerdt; R Kling; S N Wagner
Journal:  HNO       Date:  2003-06-19       Impact factor: 1.284

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.